Equities analysts expect that Davita Inc (NYSE:DVA) will announce sales of $3.01 billion for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Davita’s earnings. The lowest sales estimate is $2.91 billion and the highest is $3.22 billion. Davita posted sales of $2.78 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The firm is expected to issue its next quarterly earnings results on Tuesday, February 12th.
According to Zacks, analysts expect that Davita will report full year sales of $11.59 billion for the current fiscal year, with estimates ranging from $11.49 billion to $11.81 billion. For the next fiscal year, analysts anticipate that the company will report sales of $11.88 billion, with estimates ranging from $11.30 billion to $12.28 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Davita.
Davita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.89 by ($0.33). The business had revenue of $2.85 billion during the quarter, compared to analysts’ expectations of $2.93 billion. Davita had a return on equity of 13.87% and a net margin of 5.39%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 earnings per share.
A number of equities analysts have commented on the stock. Raymond James downgraded shares of Davita from an “outperform” rating to a “market perform” rating and set a $63.44 target price on the stock. in a research note on Sunday, December 2nd. Royal Bank of Canada upped their target price on Davita from $70.00 to $78.00 and gave the company a “sector perform” rating in a report on Thursday, November 8th. Zacks Investment Research raised Davita from a “hold” rating to a “buy” rating and set a $81.00 target price for the company in a report on Monday, October 8th. ValuEngine raised Davita from a “hold” rating to a “buy” rating in a report on Tuesday, October 9th. Finally, JPMorgan Chase & Co. raised Davita from an “underweight” rating to a “neutral” rating in a report on Thursday, September 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $79.68.
Shares of DVA stock opened at $58.96 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.82 and a debt-to-equity ratio of 2.09. Davita has a 12 month low of $58.65 and a 12 month high of $80.71. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of 17.76, a PEG ratio of 0.85 and a beta of 1.07.
Institutional investors have recently bought and sold shares of the stock. OppenheimerFunds Inc. lifted its holdings in Davita by 4.8% in the third quarter. OppenheimerFunds Inc. now owns 4,263,038 shares of the company’s stock worth $305,361,000 after buying an additional 196,721 shares during the period. Boston Partners increased its position in shares of Davita by 5.0% during the second quarter. Boston Partners now owns 2,137,616 shares of the company’s stock worth $148,436,000 after acquiring an additional 101,558 shares during the period. FMR LLC increased its position in shares of Davita by 17.2% during the third quarter. FMR LLC now owns 1,943,730 shares of the company’s stock worth $139,229,000 after acquiring an additional 285,684 shares during the period. Orbimed Advisors LLC increased its position in shares of Davita by 8.3% during the second quarter. Orbimed Advisors LLC now owns 1,689,400 shares of the company’s stock worth $117,312,000 after acquiring an additional 129,800 shares during the period. Finally, Janus Henderson Group PLC increased its position in shares of Davita by 3.0% during the second quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock worth $89,168,000 after acquiring an additional 37,362 shares during the period. Institutional investors and hedge funds own 85.76% of the company’s stock.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Article: Why do company’s buyback their stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.